Almirall Stock

Almirall EV/EBIT

The EV/EBIT (Enterprise Value to EBIT) of Almirall (ALM.MC) as of Aug 20, 2026 is 42.87. In the previous year, EV/EBIT (Enterprise Value to EBIT) was 80.44 — a change of -46.71% (lower).

EV/EBIT

42.87

YoY

-46.71%

Last updated:

EV/EBIT (Enterprise Value to EBIT) of Almirall is 2026 42.87 . EV/EBIT (Enterprise Value to EBIT) of Almirall was 2025 80.44 . It decreases by -46.71% lower compared to the previous year.

The Almirall EV/EBIT history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

PRICE-TO-EBIT
Date
PRICE-TO-EBIT
Jan 1, 2019
16.95 base
Jan 1, 2020
21.17 base
Jan 1, 2021
19.28 base
Jan 1, 2022
35.01 base
Jan 1, 2023
-335.13 base
Jan 1, 2024
48.71 base
Jan 1, 2025
40.71 base
Jan 1, 2026 (e)
63.49 base
YEARPRICE-TO-EBIT
2026 est 63.49
2025 40.71
2024 48.71
2023 -335.13
2022 35.01
2021 19.28
2020 21.17
2019 16.95
2018 27.03
2017 -4.82
2016 19.56
2015 18.48
2014 4.67
2013 -24.28
2012 20.02
2011 11.43
2010 7.51
2009 8.48
2008 -
2007 -
2006 -
Access this data via the Eulerpool API

Almirall Valuation

Details

Historical Valuation Multiples

Price-to-Earnings Ratio (P/E)

The P/E ratio divides Almirall's share price by its earnings per share. It tells you how many years of current earnings you are "paying for" when you buy the stock. A P/E of 20 means you pay $20 for every $1 of annual earnings. The S&P 500 historically trades at an average P/E of roughly 15–17. A P/E significantly above that may signal high growth expectations; one below may indicate undervaluation — or declining business quality.

Price-to-Sales Ratio (P/S)

The P/S ratio divides market capitalization by total revenue. Unlike the P/E ratio, it works even for companies that are not yet profitable, making it essential for evaluating high-growth firms. A P/S below 1.0 may indicate undervaluation, while ratios above 10 are typically reserved for fast-growing tech or SaaS companies with high expected future margins.

Price-to-EBIT Ratio

This ratio relates Almirall's market price to its operating earnings, excluding the effects of debt structure and tax jurisdiction. It is particularly useful for comparing companies across different countries or with different levels of leverage, because it focuses purely on operational profitability. Lower values suggest cheaper operational earnings.

How to Use This Chart

This chart plots Almirall's valuation multiples over time. Compare the current P/E, P/S, and P/EBIT to their own historical averages — if the current ratio is well below the multi-year average, the stock may be relatively cheap compared to its own track record. Combine this with industry comparisons: a P/E that looks high in absolute terms may be justified if Almirall grows earnings faster than its peers.

Almirall Stock analysis

What does Almirall do? The company Almirall SA is a globally operating pharmaceutical company headquartered in Barcelona, Spain. Founded in 1943 by Antonio Gallardo Ballart, the company has since become one of the leading companies in the field of dermatology and respiratory diseases. Almirall specializes in the development, manufacturing, and marketing of medications used in the treatment of skin conditions such as psoriasis or eczema, as well as respiratory diseases such as asthma or chronic bronchitis. The company focuses on close collaboration with doctors and patients to achieve the best possible therapeutic success. Almirall's business model is based on collaboration with other pharmaceutical companies to develop and bring innovative medications to the market. The company has its own research and development departments and also conducts clinical trials to test the safety and efficacy of new medications. Additionally, Almirall operates its own network of distribution and marketing partners to distribute its products worldwide. Almirall is organized into three divisions: dermatology, respiratory diseases, and other therapeutic areas. The dermatology division includes the development and marketing of medications for the treatment of skin conditions such as psoriasis and eczema. Some examples of products in this division are Skilarence, a medication for the treatment of moderate to severe psoriasis, and Kigozi, a topical medication for the treatment of atopic dermatitis. The respiratory diseases division includes the development and marketing of medications for the treatment of asthma and chronic bronchitis. The company offers a wide range of medications in this area that can be used in inhalation or tablet therapy. Some of the well-known products in this division are Alvesco, an inhaled corticosteroid for the treatment of asthma, and Ebastel, a medication for the treatment of allergic reactions. In other therapeutic areas, Almirall is involved in the development of new medications for the treatment of diseases such as ulcerative colitis or schizophrenia. For example, the company has developed Sativex, a cannabis-based medication for the treatment of multiple sclerosis-related spasticity, which is already approved in several countries. Throughout its history, Almirall has received numerous awards and recognition, including for the development of innovative medications and its work in the field of sustainability and corporate social responsibility. Through its commitment to research and development and collaboration with other pharmaceutical companies, Almirall will continue to play an important role in the global pharmaceutical industry market. Almirall is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Almirall stock

EV/EBIT (Enterprise Value to EBIT) of Almirall is 42.87 in 2026.

EV/EBIT (Enterprise Value to EBIT) of Almirall changed from 80.44 to 42.87, representing a -46.71% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EV/EBIT (Enterprise Value to EBIT) Almirall since 2006 – with annual values, charts, and detailed analysis.

The EV/EBIT ratio measures a company's enterprise value relative to its operating earnings. It accounts for debt, making it useful for comparing companies with different capital structures.

EV/EBIT = Enterprise Value / Earnings Before Interest and Taxes

To evaluate EV/EBIT (Enterprise Value to EBIT)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/EBIT (Enterprise Value to EBIT).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/EBIT (Enterprise Value to EBIT)'s Almirall with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

Valuation — Almirall

All Key Metrics — Almirall